年轻子宫内膜癌的临床特点及预后分析

目的 探讨年轻子宫内膜癌的临床特点及预后.方法 对82例确诊的子宫内膜癌患者进行回顾性分析,其中≤45岁31例(年轻组),＞45岁51例(年老组),分析两组患者的临床特点、诊治情况及预后.结果 年轻组原发性不孕率和妊娠＜3次率[38.7%(12/31)和74.2%(23/31)]明显高于年老组[3.9%(2/51)和29.4%(15/51)](P＜0.05).两组患者肌层浸润程度比较,差异有统计学意义(P＜0.05);而病理类型、组织学分级、手术病理分期、5年生存率及复发时间比较,差异均无统计学意义(P＞0.05).结论 不孕或少孕为年轻子宫内膜癌的发病因素;年轻子宫内膜癌肌层浸润程度较年老患者轻,病理类型、组织学分级、手术病理分期与年老患者相似,但并没有获得比年老者更好的预后.

Abstract：

Objective To investigate the clinical characteristics and prognosis of young patients with endometrial cancer. Methods Eighty-two cases with endometrial cancer were analyzed retrospectively,31 cases in the young group were ≤ 45 years old, and 51 cases in the old group were ＞ 45 years old. The clinical characteristics, diagnosis, treatment and prognosis between the two groups were compared. Results Twelve cases with primary infertility took up 38.7% in the young group,23 cases with less than 3 times of pregnancy occupied 74.2%, and there was no statistical difference,compared with the old group [3.9%(2/51)and 29.4% (15/51)] (P＜0.05). There was statistically significant between the two groups in myometrial invasion (P ＜ 0.05 ); while there was no significance between the two groups in pathological type, histological grade,clinical stage, 5-year survival rate and recurrence period (P＞0.05). Conclusion Infertility or less pregnancy are risk factors for endometrial cancer in the young; the degree of endometrial invasion in the young is more shallow than that in the old; there is no significant difference between the young and the old in pathological type, histological grade and clinical stage; but the prognosis is similar between the young and the old patients.     

头颈部腺样囊性癌58例临床病理及预后分析

目的 研究头颈部腺样囊性癌的临床病理及预后因素.方法 回顾性收集1999年1月至2007年12月治疗的头颈部腺样囊性癌患者58例,通过对其临床病理资料的收集和预后随访,分析影响腺样囊性癌预后的因素.结果 单因素分析发现,组织病理类型、嗜神经侵袭、血管侵袭、肿瘤复发、肿瘤远处转移以及TNM分期与腺样囊性癌的预后有关(P＜0.05).多因素分析显示TNM分期、组织病理类型筛孔型以及嗜神经侵袭是腺样囊性癌的独立预后因子(P＜0.05).结论 组织病理类型、TNM分期、嗜神经侵袭、血管侵袭、肿瘤复发以及肿瘤远处转移是腺样囊性癌重要的预后因子.

Abstract：

Objective To approach the prognostic factors of head and neck adenoid cystic carcinoma.Methods Fifty-eight head and neck adenoid cystic carcinomas were treated from January 1999 to December 2007.The demographic and clinicopathological data were obtained from a retrospective chart review.The follow-up and survival analysis were carried out to analyze the significant prognostic factors.Results Using the univariate analysis,the variables,such as histologic type,perineural invasion,vascular invasion,recurrence,metastasis and TNM stage were found significantly associated with a worse prognosis (P ＜ 0.05 ).Multivariate analysis showed that histologic type,perineural invasion and TNM stage had an independent prognostic effect on survival (P ＜ 0.05 ).Conclusion The variables including histologic type,TNM stage,perineural and vascular invasion,recurrence and metastasis are important prognostic factors for head and neck adenoid cystic carcinoma.     

338例早期胃癌的临床分析

目的 探讨早期胃癌(EGC)淋巴结转移与临床病理特征的关系,找出影响预后因素.方法 回顾性分析1999年7月至2009年6月行胃癌根治术338例EGC患者的临床资料,分析淋巴结转移与肿瘤大小、组织学类型、浸润深度之间的关系;应用Kaplan-Meier法对随访患者资料进行影响预后因素及生存率分析.结果 淋巴结转移与肿瘤大小、浸润深度有关,差异有统计学意义(P<0.05或<0.01).63例随访患者5年生存率为92.1%;肿瘤浸润黏膜层患者5年生存率为97.1%,肿瘤浸润黏膜下层患者5年生存率为85.7%;肿瘤浸润深度、肿瘤大小与EGC术后生存率相关(P值分别为0.043、0.004).结论 根据肿瘤大小、浸润深度、淋巴结转移等生物学特点,合理选择手术方案,有助于提高EGC患者的5年生存率,改善预后.

Abstract：

Objective To find out the relationship between lymph node metastasis and clinical pathological specificity, the prognostic factors for the purpose of improving survival of early gastric cancer (EGC) and quality of life. Methods The clinical data of the 338 EGC patients from July 1999 to June 2009 was analyzed retrospectively, includirg the possible relationship of lymph node metastasis, the size of tumor,types of histopathology,depth of infiltration. Using Kaplan-Meier method to process suvival rate,immunohistochemistry method to detect the micrometastasis. Results Lymphnode metastasis was relative to the size of tumor, depth of infiltration (P < 0.05 or < 0.01). Total 5-year survival rate was 92.1%, intramucosa 5-year survival rate 97.1%, submucosa 5-year survival rate was 85.7% in 63 followed up patients, the survival rate of EGC was related with depth of infiltration and size of tumor (P = 0.043,0.004). Conclusion By precisely estimating depth of infiltration, the size of tumor and correct estimating the state of lymph node metastasis, choosing right 5-year surgical protocol can improve EGC survival rate and prognosis.     

Eribulin for heavily pre-treated metastatic breast cancer patients

AIM: To discuss treatment with eribulin in clinical practice outside a clinical trial.METHODS: Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeutic eribulin mesylate, a synthetic analog of a natural marine product, were identified. Information on patients' characteristics and treatment outcomes was extracted. Treatment with eribulin mesylate was initiated at the recommended dose of 1.4 mg/m2 on days 1 and 8 of a 21-day cycle in 17 patients and at a decreased dose of 1.1 mg/m2 on days 1 and 8 of a 21-day cycle in 4 patients due to comorbidities and frailty. Efficacy of the drug was evaluated using the revised Response Evaluation Criteria in Solid Tumors criteria. Progression-Free Survival and overall survival(OS) were calculated using the Kaplan-Meier method starting from the date of eribulin therapy initiation to the date of disease progression documentation or death, respectively.RESULTS: The median age of patients at the time of eribulin mesylate treatment was 53 years(range 34-75). Sixteen patients had estrogen receptor(ER) and/or partial response(PR) positive disease and 5 had ER/PR negative disease(all triple negative). Eight patients had received 2 or 3 previous lines of chemotherapyfor metastatic disease and 13 patients had received 4 or more lines of treatment. The median number of cycles of eribulin received was 3(range 1-16 years). All patients, except one, discontinued treatment due to progressive disease and one patient due to adverse effects. Six patients had a dose reduction due to side effects. All patients had progressed at the time of the report with a median time to progression of 3 mo(range 1 to 14 mo). Fifteen patients had died with a median OS of 7 mo(range 1-18 mo). Six patients were alive with a median follow-up of 13.5 mo(range 7 to 19 mo).CONCLUSION: This series of patients confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population consistent with phase Ⅱ and Ⅲ trials.     

北京市某传染病医院14 398例乙型肝炎住院患者特征及费用分析

目的 了解北京市某传染病医院2002-2007年14 398例次乙型肝炎(乙肝)出院患者人口学和疾病特征及住院费用,分析住院总费用相关影响因素.方法 采用描述性分析方法 分析乙肝出院患者人口学和疾病特征及住院费用;应用多元线性回归后退法分析影响总住院费用的凶素.结果 乙肝住院患者男性高于女性(2.9:1);平均年龄45.2岁.乙肝出院患者死亡比例为7%,平均年龄为55岁.住院患者平均费用为16947.91元;其中肝硬化患者费用最高,病毒携带患者费用最低.费用构成中药费所占比重最大(62.4%);医疗费用的影响因素为病种、住院时间、疾病程度(是否手术、合并及伴随疾病)、患者人口学特征、居住地区.结论 乙肝住院患者男性比例高于女性;如果发病初期未得到有效控制,发展为慢性肝炎、肝硬化或肝癌,合并症多,预后较差,相应的医疗费用增加.医疗费用不仅与疾病的病种有关,还与疾病的复杂程度、患者特征相关.

Abstract：

Objective This article was to focus on the study of patient's profile,type and distribution of the disease and the related factors contributing to medical cost on 14398 cases of hospitalized patients with hepatitis B from a hospital of infectious diseases located in Beijing,in order to provide basic information on optimizing the prevention and treatment strategies.Methods Information on hospital admission of patients、with hepatitis B was collected and SPSS 16.0 statistics software package was used to analyze the profile,disease patterns distribution,structure of medical costs and main contributors related to medical costs.Results Through analysis,we found that the proportion of male patients was much bigger than that of female patients,with ratio as 2.9.The average age of patients with hepatitis B was 45.2 years old.The treatment process was time consuming,and the mortality rate was hiigh.Our data showed that the mortality of hospitalized patients was up to 7%and the average age of death was 55 years old.Hepatitis B infection was easy to develop into chronic,cirrhosis and even liver cancer,Fortreatment cost,the largest cost share was the drugs being used which accounted for 62.4%.In terms of health care costs,it was high and the total cost of hospitalization was related to the following factors:days of hospitalization;complexity of the disease condition and the factors as the severity of the disease complications as surgery,frequencies of rescue,type of disease etc;basic information of the patients as age,occupation,origin.Conclusion Compared with other diseases,the proportion of male patients with hepatitis B was much higher than that of the famale.Hepatitis B had a longer duration and difficult,treatment high cost of medical care,poor prognosis,high mortality rate;Cost control,Call not simply fixcd by single disease,but by complexity of the disease and patient characteristics.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

持续皮下胰岛素输注和胰岛素每日多点注射治疗2型糖尿病的成本效果分析

Objective To observe the cost-effectiveness of using continuous subcutaneous insulin infusion (CS Ⅱ) and multi-point daily insulin injections (MDI) in controlling blood sugar in the newly hospitalized type 2 diabetes patients. Methods Retrospective analysis on 86 cases taking CS Ⅱ and 103 cases using MDI on a 'blood sugar control program' among the newly hospitalized patients with type 2 diabetes. The period for observation was 2 weeks, using cost-effectiveness analysis methods to evaluate the two treatment programs. Results After two weeks of treatment, the effectiveness in the control of blood sugar in CS Ⅱ group was similar to the MDI group, with no significant difference(P<0.05) and the adverse reactions were similar. Costs in the CS Ⅱ program (Yuan/person) was less than in the MDI program (1478.34 vs. 1620.46), with significant differences (P< 0.05). The cost-effectiveness ratios (C/E) were 15.07 in the CS Ⅱ group, and 16.34 in the MDI group, with no significant difference (P>0.05). In order to further reduce the cost of CS Ⅱ group as a reference, the incremental cost-effectiveness ratio (△C/ △E)ofthe MDI group was 129.20. Conclusion Costs-effective of the CS Ⅱ program was better than the MDI one in treating the newly hospitalized patients with type 2 diabetes, suggesting that CS Ⅱ program might be a better choice for hospitals to carry on an intensive insulin therapy program.     

225例子宫内膜癌患者生存预后相关因素的分析

目的：探讨子宫内膜癌的预后及其相关因素,为子宫内膜癌的临床诊治提供参考。方法：回顾性分析2003年1月—2010年6月北京协和医院妇产科收治的225例子宫内膜癌患者的临床资料,计算生存率,Kaplan-Meier法筛选危险因素,用比例危险度回归模型（Cox回归）对危险因素进行多因素分析。结果：225例患者5年累积生存率为90.6%。单因素Kaplan-Meier分析显示,子宫内膜癌生存率与手术病理分期、组织学分级、肌层浸润深度、病理类型、术后辅助治疗、淋巴结转移和腹腔细胞学有关（P＜0.05）。各手术分期患者中,行淋巴结剔除者和未行淋巴结剔除者的生存率差异无统计学意义（P＞0.05）。早期子宫内膜癌患者术后接受辅助治疗和未接受辅助治疗的患者生存率差异无统计学意义（P＞0.05）。Cox回归行多因素分析显示,手术分期、病理类型、组织学分级是影响子宫内膜癌预后的独立危险因素（P＜0.05）,非子宫内膜样癌、手术病理分期晚和组织学分级差的患者预后差。结论：子宫内膜癌总体预后良好,手术分期晚、非子宫内膜样癌、组织学分级差是子宫内膜癌预后的独立危险因素,肌层浸润深度、腹腔冲洗液等与其预后无关。     

子宫内膜癌的预后因素分析

目的:探讨影响子宫内膜癌预后的风险因素。方法:回顾性分析手术治疗的子宫内膜癌患者381例的临床与病理资料。单因素和多因素分析采用Cox比例风险模型,生存率的计算采用Kaplan-Meier法,生存率的比较采用log-rank检验。结果:经单因素分析显示FIGO分期、病理类型、病理分级、肌层浸润、宫颈浸润、附件转移、盆腔淋巴结转移、腹主动脉旁淋巴结转移、远处转移与子宫内膜癌的预后密切相关;经多因素分析显示病理分级G3、附件转移对子宫内膜癌预后影响具有显著性意义。病理分级G3、附件转移患者淋巴结转移率明显升高,5年生存率显著降低。结论:病理分级G3、附件转移是影响子宫内膜癌预后的重要风险因素,在设计子宫内膜癌的治疗方案时应重视患者的病理分级、附件转移情况,选择合适的治疗方案。     

绝经后子宫内膜癌临床及病理特点分析

目的:探讨绝经与子宫内膜癌的关系。方法:分析1997年1月～2002年12月128例绝经后子宫内膜癌患者资料,并以同期未绝经的105例子宫内膜癌患者作为对照,比较其临床病理特点,用寿命表法计算两者的生存率。结果:绝经后子宫内膜癌高血压的发生率显著高于未绝经组,而未绝经组中肥胖及不孕的发生率高于已绝经组。比较两组的高危病理类型、病理分级、肌层浸润深度、手术病理分期及5年存活率均有统计学差异。结论:绝经后发生的子宫内膜癌预后差与其临床病理特点有关。     

胃癌手术患者预后影响因素分析

目的探讨胃癌患者术后生存的影响因素。方法应用单因素和多因素Cox回归分析方法,回顾性分析2000年1月-2005年12月有完整临床资料和随访资料的289例胃癌患者临床资料。结果 289例胃癌患者术后1年、3年和5年生存率分别为80.96%、50.87%和42.91%;单因素分析表明：肿瘤浸润深度、淋巴结转移、远处转移、Bor-rmann分型、肿瘤部位、组织病理学分级、TNM分期和肿瘤的根治度、化疗疗程对胃癌患者的5年生存率均有影响（P〈0.05）。Cox回归分析显示：Borrmann分型、病理组织学分级、肿瘤浸润深度、淋巴结及远处转移,TNM分期和化疗6个疗程7个因素是影响胃癌术后生存的独立因素（P〈0.05）。结论胃癌的Borrmann分型、病理组织学分级、肿瘤浸润深度、淋巴结转移、远处转移、TNM分期和化疗6个疗程是影响其术后生存的重要因素。     

子宫腺肌病合并子宫内膜癌的临床病理分析

目的 研究子宫腺肌病合并子宫内膜癌患者的临床病理特征,并比较子宫腺肌病合并子宫内膜癌患者与单纯的子宫内膜癌患者的高危影响因素及其对复发与预后意义.方法 对凉山州第二人民医院妇产科2005年2月至2015年7月期间治疗的307例子宫内膜癌患者的临床病理资料进行了回顾性分析,其中子宫腺肌病合并子宫内膜癌患者31例(A组,10.1％),其余276例为单纯的子宫内膜癌患者(B组,89.9％),比较两组患者手术病理分期、病理类型、肌层浸润深度、雌激素受体和孕激素受体的表达、细胞学分型、腹水细胞学、淋巴结转移,复发率、3年无病存活率、3年总存活率等资料.结果 A组相比于B组,其肌层深度浸润较浅、组织分化程度好、PR阳性检测率高、ER阳性检测率高、复发率低、3年无病存活率高、3年总存活率高,差异均具有统计学意义(x2值分别为4.065、6.285、4.480、6.813、4.98、12.45、17.87,均P＜0.05).两组患者手术病理分期、年龄、绝经率、体重指数、腹水细胞学阳性率、淋巴结转移及病理类型比较差异均无统计学意义(x2值分别为1.47、2.31、1.22、1.76、1.21、2.04、2.57,均P＞0.05).结论 子宫腺肌病合并子宫内膜癌可能为雌激素依赖性肿瘤,肌层浸润较浅,组织分化好,相较单纯的性子宫内膜癌患者其高危因素少.患者术后复发率低,3年无病存活率高,3年总存活率高,预后较好.     

老年子宫内膜癌患者治疗方式探讨

目的 分析老年子宫内膜癌患者的临床特征、预后相关因素,探讨其最佳治疗方式.方法 对268例老年子宫内膜癌患者的临床病理资料、生存情况进行回顾性分析,评价影响其预后的因素.结果 单因素方差分析显示治疗方式、手术-病理分期、病理分级与老年子宫内膜癌患者预后有显著相关性(P<0.01).COX多元逐步回归分析显示手术-病理分期、病理分级为预测老年子宫内膜癌患者预后的独立因素(P值分别为0.002、0.000).结论 手术-病理分期、治疗方式及病理分级与老年子宫内膜癌预后密切相关;手术-病理分期及病理分级为预后独立因素.老年子宫内膜癌患者的治疗应结合其高危因素,采取个体化、综合化的治疗方式.     

子宫内膜腺癌组织中Bcl—2蛋白表达的研究

为探讨Ｂｃｌ－２蛋白在子宫内膜腺癌组织中的表达状况，其病理学与临床意义，本组应用抗Ｂｃｌ－２单克隆抗体对３４例子宫内膜腺癌细胞石蜡标本行Ｂｃｌ－２蛋白免疫组织化学测定（ＳＡＢＣ法）。结果发现Ｂｃｌ－２蛋白在子宫内膜腺癌组织中表达的阳性率为４７％，其阳性表达与肿瘤组织学分期、肌层浸润深度及患者预后有关（Ｐ〈０．０５）。说明Ｂｃｌ－２蛋白表达与子宫内膜腺癌的某些病理学特征及生物学行为之间存在的关系。应     

子宫内膜癌患者PTEN的表达及其临床意义探讨

目的:研究抑癌基因PTEN在子宫内膜腺癌组织中的表达及其与预后的关系。方法:采用免疫组化SP法检测103例子宫内膜腺癌病理标本PTEN的表达,并对其中54例患者进行5年随访,对PTEN表达情况与生存率进行相关性分析。结果:①子宫内膜腺癌患者PTEN阳性表达率明显高于健康对照组(χ2=83.96,P<0.001)。②子宫内膜腺癌组织分级G3级、临床分期Ⅲ-Ⅳ期、浸润超过1/2肌层厚度及有淋巴结转移者PTEN阳性表达明显降低。③PTEN阳性率与子宫内膜癌术后5年存活率有关(χ2=7.64,r=0.3521,P<0.01),PTEN高表达者,术后5年存活率也越高。结论:子宫内膜癌患者存在PTEN表达下调,PTEN表达与子宫内膜癌临床病理分级、分期、癌细胞浸润、转移及预后有关;子宫内膜组织PTEN检测对诊断子宫内膜癌并判定其恶性程度和预后具有重要意义。     

细胞角质蛋白对诊断子宫内膜癌淋巴微转移的研究

目的:探讨细胞角质蛋白(CK)对诊断子宫内膜癌淋巴微转移的意义及影响其检出率的因素。方法:对2005年1月～2009年6月在吉林省肿瘤医院妇瘤科及吉林大学第二医院进行手术治疗且经一般病理诊断40例子宫内膜癌患者无转移的淋巴结240枚(实验组1)和80例子宫内膜癌患者有转移的淋巴结440枚(实验组2)临床资料进行回顾性分析。结果:病理诊断阳性的淋巴结CK检测全部阳性,病理诊断阴性的淋巴结CK检测并非全部阴性,阳性率提高了19.2%(46/240),经单因素分析肿瘤组织分化程度、浸润深度、病理类型及手术分期均影响其检查的因素(P0.05)。结论:CK能够提高淋巴结阳性的检出率,从而正确行子宫内膜癌手术-病理分级,指导子宫内膜癌的术后辅助治疗,提高预后。